Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Arizona
Clinical trial register · United States · industry-sponsored

Clinical Trials in Arizona, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 72 Florida 72 Georgia 47 Arizona 43 Illinois 39
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca113 Eli Lilly and Company96 AbbVie74 Merck Sharp & Dohme LLC62 Janssen Research & Development, LLC49 Clear sponsor filter
State
California72 Florida72 Georgia47 Arizona43 Illinois39
All 42 states
Target enrolment
to

Trials with a site in Arizona

43 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Sanofi
Phase 1/2
640
Arizona, California, Florida, Georgia, Illinois, Kansas, New York, South Carolina
2026-08-03
Recruiting
Sanofi
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Missouri
2026-05-12
Recruiting
Sanofi
Observational
2,500
Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland
2026-04-01
Recruiting
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Indiana, Louisiana, Michigan, Missouri
2026-01-16
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2026-01-14
Recruiting
Sanofi
Phase 2
144
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2025-12-29
Recruiting
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Recruiting
Sanofi
Phase 2
208
Arizona, California, Florida, Georgia, Iowa, Louisiana, Missouri, Nevada
2025-11-06
Recruiting
Sanofi
Phase 1/2
104
Arizona, California, Florida, Georgia, Illinois, Maryland, Nevada, North Carolina
2025-10-09
Recruiting
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-08
Recruiting
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-01
Recruiting
Sanofi
Phase 3
942
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-09-17
Recruiting
Sanofi
Phase 3
942
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2025-09-16
Recruiting
Sanofi
Phase 3
90
Arizona, California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, Minnesota
2025-08-18
Recruiting
Sanofi
Phase 3
192
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-08-12
Recruiting
Sanofi
Phase 3
723
Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho, Kentucky
2025-08-06
Recruiting
Sanofi
Phase 2
99
Arizona, California, Florida, Georgia, Iowa, Kansas, Massachusetts, Michigan
2025-06-03
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Alabama, Arizona, Kansas, Pennsylvania
2025-04-01
Active, closed
Sanofi
Phase 2
204
Arizona, Connecticut, Florida, Illinois, Michigan, New York, Ohio, Pennsylvania
2025-03-28
Recruiting
Sanofi
Phase 2
64
Arizona, California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan
2025-03-17
Active, closed
Sanofi
Phase 3
2,360
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2025-02-18
Active, closed
Sanofi
Phase 2
260
Arizona, Connecticut, Florida, Illinois, Michigan, Mississippi, Nevada, New York
2024-12-10
Active, closed
Sanofi
Phase 1/2
66
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2024-11-21
Active, closed
Sanofi
Phase 2
556
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-11-07
Recruiting
Sanofi
Phase 1
87
Arizona, Florida, Minnesota, New Jersey, Pennsylvania
2024-10-30
By invitation
Sanofi
Phase 2
900
Arizona, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, North Carolina
2024-09-30
Active, closed
Sanofi
Phase 2
229
Arizona, California, Colorado, Florida, Idaho, Kansas, Massachusetts, Michigan
2024-08-29
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2024-08-21
Active, closed
Sanofi
Phase 2
185
Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Massachusetts
2024-06-20
Active, closed
Sanofi
Phase 3
1,541
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2024-05-08
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-04-16
Active, closed
Sanofi
Phase 3
464
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2024-02-29
By invitation
Sanofi
Phase 3
90
Arizona, Florida, Illinois, Kentucky, Minnesota, New York, North Carolina, Ohio
2024-01-03
Active, closed
Sanofi
Phase 3
943
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-27
Active, closed
Sanofi
Phase 3
1,655
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-13
Recruiting
Sanofi
Phase 3
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Maryland
2023-10-10
Active, closed
Sanofi
Observational
200
Arizona, California, Colorado, Florida, Illinois, Indiana, Iowa, Massachusetts
2023-06-30
Active, closed
Sanofi
Phase 2
999
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2023-04-03
Active, closed
Sanofi
Phase 2/3
1,856
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-08-22
Active, closed
Sanofi
Phase 4
1,339
Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Louisiana
2021-12-16
Active, closed
Sanofi
Phase 2
109
Alabama, Arizona, California, Florida, New Mexico, New York, Oklahoma, Tennessee
2021-11-10
Active, closed
Sanofi
Phase 2
129
Arizona, Florida, North Carolina, Wisconsin
2021-06-07
Active, closed
Sanofi
Observational
1,860
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2019-08-15
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/arizona

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies with a site in Arizona that also match the filters currently applied.

How many clinical trials are recruiting in Arizona?

21 of the 43 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Arizona), 43 studies
PhaseStudiesRecruitingShare
Phase 3191144.2%
Phase 213430.2%
Observational429.3%
Phase 1/2327%
Phase 4214.7%
Phase 1112.3%
Phase 2/3102.3%

Most active sponsors

Lead sponsors with the most studies (Arizona)
Lead sponsorStudiesRecruiting
Sanofi4321
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.